Bharat Immunologicals (India) Probability of Target Price Finishing Over 21.05

BIBCL -- India Stock  

INR 16.15  0.95  5.56%

Bharat Immunologicals probability of target price tool provides mechanism to make assumptions about upside and downside potential of Bharat Immunologicals Biologicals Corp Ltd performance during a given time horizon utilizing its historical volatility. Please specify Bharat Immunologicals time horizon, a valid symbol (red box) and a target price (blue box) you would like Bharat Immunologicals odds to be computed. Check also Trending Equities.
 Time Horizon     30 Days    Login   to change
Refresh Odds

Bharat Immunologicals Target Price Odds to finish over 21.05

Current PriceHorizonTarget PriceOdds to move over  21.05  or more in 30 days
 16.15 30 days 21.05  NEAR 1%
Based on normal probability distribution, the odds of Bharat Immunologicals to move over  21.05  or more in 30 days from now is near 1% (This Bharat Immunologicals Biologicals Corp Ltd probability density function shows the probability of Bharat Immunologicals Stock to fall within a particular range of prices over 30 days) . Probability of Bharat Immunologicals price to stay between its current price of  16.15  and  21.05  at the end of the 30-day period is about 30.6%.
Assuming 30 trading days horizon, Bharat Immunologicals has beta of 0.4568 . This suggests as returns on market go up, Bharat Immunologicals average returns are expected to increase less than the benchmark. However during bear market, the loss on holding Bharat Immunologicals Biologicals Corp Ltd will be expected to be much smaller as well. Additionally Bharat Immunologicals Biologicals Corp Ltd has an alpha of 0.5947 implying that it can potentially generate 0.5947% excess return over DOW after adjusting for the inherited market risk (beta).
 Bharat Immunologicals Price Density 
 
      
Current Price   Target Price   
α
Alpha over DOW
=0.59
β
Beta against DOW=0.46
σ
Overall volatility
=0.54
Ir
Information ratio =0.31

Bharat Immunologicals Alerts

Bharat Immunologicals Alerts and Suggestions
The company reported revenue of 347.99 M. Net Loss for the year was (51.73 M) with profit before overhead, payroll, taxes, and interest of 48.93 M.
Latest headline from in.reuters.com: ICRA ratings for Indian debt instruments-Jul 27
Check also Trending Equities. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.